Clinical trial NCT02962388: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Official title: A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Essential Thrombocythemia
Keywords: efficacy
safety
Lead sponsor: French Innovative Leukemia Organisation
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2016-11-11
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective national multicenter randomized open label phase IIb RUXBETA trial.

Detailed description: A randomized, open label, multicenter phase IIb study to evaluate the efficacy and safety of Ruxolitinib versus best available therapy in patients with high risk essential thrombocythemia, who are resistant or intolerant to hydroxyurea.

Eligibility criteria: Inclusion Criteria:

Target Population

* Men and women, age more than or equal18 years and less than 75 years.
* Confirmed diagnosis of Essential Thrombocythemia for at least 6 months, according to the 2008 WHO criteria, with a high-risk status.
* Patients must have a treatment history for ET that meet the definition of resistance or intolerance to hydroxyurea therapy according to the ELN criteria as follow:

  * Platelets more than 600.0109/L after 3 months (12 weeks) of treatment at a dose over 2g/day.
  * Platelets more than 400.0 109/L and WBC less than 2.5109/L, whatever the dose of HU.
  * Platelets more than 400.0 109/L and Hb less than 10g/dl whatever the dose of HU.
  * Leg ulcers or other unacceptable muco-cutaneous toxicity.
  * HU-related fever.
* ECOG Performance Status (ECOG PS) less than or equal 2 at screening and at baseline.

Adequate Organ Function:

* Direct bilirubin less than 2.0 times the institutional Upper Limit of Normal (ULN).
* Hepatic enzymes (AST, ALT) less than or equal 2.5 times the institutional ULN.
* Adequate renal function at screening as demonstrated by MDRD-eGFR more than 30 mL/min/1.73m2.
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during and after the study.

  * A male subject of fathering potential must use an adequate method of contraception to avoid conception during and after the study to minimize the risk of pregnancy.
  * For females and males, these restrictions apply for 24 hours after the last dose of study drug.
* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin hCG pregnancy test at Screening.
* Signed Written Informed Consent.
* Health insurance coverage.

Exclusion Criteria:

* Patients with thrombocytosis related to another MPN than ET
* Patients previously treated with a JAK2 inhibitor, Anagrelide or Interferon-alpha and prior history of therapy other than Hydroxyurea
* Contraindication to Ruxolitinib, Anagrelide or Interferon-alpha (if no eligible for anagrelide), hypersensitivity to an excipient

Medical history and concurrent diseases:

* Clinically significant cardiac disease (NYHA Class III or IV).
* Chronic hepatocellular disease.
* Subjects with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Ruxolitinib
* Subjects with clinically significant bacterial, fungal, parasitic or viral infection which requires therapy:

  * Subjects with acute bacterial infections requiring antibiotic use should delay screening/enrolment until the course of antibiotic therapy has been completed.
  * Subjects with active hepatitis A, B or C or with HIV positivity at screening.
  * Subjects with diagnosed primary immunodeficiency syndromes such as X-Linked a gammaglobulinemia and common variable immune deficiency.
  * Subject with medical history of tuberculosis
* History of progressive multifocal leucoencephalopathy (PML).
* Other malignant disease during the last 5 years prior to the inclusion except treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, with no evidence for recurrence in the past 3 years.
* History of significant bleeding disorder not related to the ET.

  * Diagnosed congenital bleeding disorders,
  * Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VIII antibodies),
  * Ongoing or recent (3 months) significant gastrointestinal bleeding.
* Subjects with an uncontrolled undercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol.
* Subjects being treated concurrently with a potent systemic inhibitor of CYP3A4 at the time of screening.
* Subjects being treated concurrently with any prohibited medications.
* Women who are pregnant or breastfeeding are not eligible for this study.
* Inability to freely provide consent through judiciary or administrative condition.
* Ongoing participation to another clinical investigational study.

Primary outcomes:
measure: Failure-free patients
timeFrame: month 12
Secondary outcomes:
measure: Complete hematologic response
timeFrame: 48 months
measure: AE/SAE
timeFrame: 48 months
measure: Median dose
timeFrame: 48 months
measure: Thrombotic and hemorrhagic events
timeFrame: 48 months
measure: Quality of life questionnaire
timeFrame: 48 months
Other outcomes:
Locations:
city: Tours
country: France
facility: FILO
Study officials:
affiliation: France Intergroupe Syndromes Myéloprolifératifs
name: Stéphane GIRAUDIER, MD PD
role: PRINCIPAL_INVESTIGATOR
affiliation: France Intergroupe Syndromes Myéloprolifératifs
name: LYDIA ROY, MD
role: PRINCIPAL_INVESTIGATOR
References: